Core Viewpoint - The company, Gilead Sciences (stock code: 1672), announced a financing plan through the placement of existing shares and the issuance of new shares, raising approximately HKD 470 million for clinical trials and operational needs [1] Group 1: Financing Details - The company plans to place 52,400,000 existing shares and issue 28,820,000 new shares at a price of HKD 16.45 per share, representing a discount of about 9.9% compared to the closing price of HKD 18.26 on August 18, 2025 [1] - The placement of existing shares accounts for approximately 5.44% of the current issued share capital, while the new shares will represent about 2.99% of the existing share capital [1] - The funds raised will be allocated with approximately HKD 420 million for clinical trials related to subcutaneous and oral peptide candidates for obesity, and about HKD 50 million for working capital and other general corporate purposes [1] Group 2: Regulatory and Completion Aspects - The issuance is conducted under a general mandate granted by the shareholders' meeting, and the subscription will be completed upon meeting relevant conditions, but no later than 14 days after August 19, 2025 [1]